Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Earnings Roundup: Shinogi & Co.'s China Deal And Astellas Pharma Inc.'s Label Woes

This article was originally published in The Pink Sheet Daily

Executive Summary

Shionogi rebounds from U.S. acquisition woes with C&O Pharmaceutical for China; Astellas ponders Mirabegron's reproductive warning.

You may also be interested in...

Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2

TOKYO - Astellas provided an update on development for blockbuster-hopeful mirabegron, and the main theme of its progress appears to be safety, or rather waiting for safety data. The company delayed U.S. and EU filings for the drug on regulatory requests for more safety data to assess cardiovascular risk. The company rescheduled mirabegron's FDA filing for 2Q/FY2011, and now everyone is waiting for full results on additional safety studies

How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 1 of 2)

SAN FRANCISCO - Big pharma may need to take a leap of faith to close deals in China, accepting greater risk in areas such as regulatory compliance and quality control, according to panelists during the 29th annual J.P. Morgan Healthcare conference in San Francisco

Shionogi Spurns Europe, Places Bets On Asia For Global Expansion - Bio Expo Japan

TOKYO - Shionogi, set on global expansion, has rejected initial plans to expand into Europe, instead turning to emerging markets in Asia


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts